: Using 2 global postmarketing surveillance databases, Goldman and colleagues report that progressive multifocal leukoencephalopathy (PML), a viral disease associated with profound immunosuppression, occurs in approximately 0.9 cases per 1000 recipients of CD19-directed CAR T-cell therapy. The risk of PML appears higher with CAR T-cell therapy than other cancer therapies, but its precise role cannot be distinguished from antecedent therapies that these patients receive.
Goldman, A., Raschi, E., Chapman, J., Santomasso, B.D., Pasquini, M.C., Perales, M., et al. (2023). Progressive multifocal leukoencephalopathy in patients treated with chimeric antigen receptor T cells. BLOOD, 141(6), 673-677 [10.1182/blood.2022017386].
Progressive multifocal leukoencephalopathy in patients treated with chimeric antigen receptor T cells
Raschi, EmanuelSecondo
;
2023
Abstract
: Using 2 global postmarketing surveillance databases, Goldman and colleagues report that progressive multifocal leukoencephalopathy (PML), a viral disease associated with profound immunosuppression, occurs in approximately 0.9 cases per 1000 recipients of CD19-directed CAR T-cell therapy. The risk of PML appears higher with CAR T-cell therapy than other cancer therapies, but its precise role cannot be distinguished from antecedent therapies that these patients receive.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
